---
url: https://www.servicesaustralia.gov.au/high-risk-neuroblastoma
title: High-risk neuroblastoma - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:40:52.169Z
source: servicesaustralia.gov.au
---
# High-risk neuroblastoma

The PBS subsidises eflornithine for patients with high-risk neuroblastoma.

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Treatment specifics](#a3)
-   [Authority applications](#a4)
-   [More information](#a5)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with eflornithine under the _National Health Act 1953_, section 100 for patients with high-risk neuroblastoma.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing eflornithine.

## Section 100 arrangements

### eflornithine

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

-   an approved private hospital
-   a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

## Treatment specifics

To be eligible for PBS-subsidised treatment with eflornithine, patients must be treated by either a:

-   paediatric oncologist
-   haematologist.

## Authority applications

### Applying for initial treatment

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

Applications for initial authority approval to prescribe PBS-subsidised eflornithine to treat high-risk neuroblastoma can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and use [HPOS Form upload](/hpos?context=20)
-   in writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [high-risk neuroblastoma - eflornithine - initial authority application form](/pb384?context=20)
-   relevant attachments.

### Applying for initial grandfather treatment

For patients who received non-PBS-subsidised eflornithine treatment before 1 August 2025 for high-risk neuroblastoma, apply for initial grandfather authority approval either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised eflornithine to treat high-risk neuroblastoma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
